Genmab A/S (NASDAQ:GMAB – Get Free Report) has been assigned an average rating of “Moderate Buy” from the ten analysts that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $45.20.
Several research firms recently commented on GMAB. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a research report on Wednesday, October 16th. BMO Capital Markets restated an “outperform” rating and issued a $48.00 price objective (up from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Truist Financial lowered their target price on shares of Genmab A/S from $53.00 to $50.00 and set a “buy” rating on the stock in a research note on Monday, September 9th. Redburn Atlantic assumed coverage on shares of Genmab A/S in a research note on Tuesday, October 8th. They issued a “buy” rating for the company. Finally, Morgan Stanley restated an “equal weight” rating and set a $31.00 price objective on shares of Genmab A/S in a research report on Wednesday, September 11th.
Get Our Latest Analysis on GMAB
Institutional Investors Weigh In On Genmab A/S
Genmab A/S Stock Up 1.6 %
GMAB stock opened at $21.50 on Monday. The stock has a 50-day simple moving average of $22.64 and a two-hundred day simple moving average of $25.63. Genmab A/S has a twelve month low of $20.34 and a twelve month high of $32.88. The firm has a market capitalization of $14.23 billion, a PE ratio of 20.87, a PEG ratio of 0.65 and a beta of 0.99.
Genmab A/S (NASDAQ:GMAB – Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.03). Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. The firm had revenue of $816.10 million for the quarter, compared to analysts’ expectations of $838.20 million. During the same period in the prior year, the firm posted $0.47 EPS. On average, equities research analysts anticipate that Genmab A/S will post 1.3 EPS for the current fiscal year.
Genmab A/S Company Profile
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Featured Articles
- Five stocks we like better than Genmab A/S
- Russell 2000 Index, How Investors Use it For Profitable Trading
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- The Most Important Warren Buffett Stock for Investors: His Own
- 3 Penny Stocks Ready to Break Out in 2025
- Basic Materials Stocks Investing
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.